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Left ventricular assist device (LVAD) implantation 
have become a standard therapy for selected patients 
with advanced heart failure (HF). Especially for older 
patients with end-stage HF who are deemed ineligible 
for heart transplantation, LVAD therapy has become 
their last resort. Though the survival of these patients on 
LVAD support is superior to optimal medical therapy, 
the use of LVAD is associated with high morbidity and 
mortality. Common complications include infection, 
bleeding, neurologic events, and right-sided heart 
failure (RHF). The latter has been shown in a cecent 
analysis of the largest European LVAD registry, the 
European registry of mechanical circulatory support 
(EUROMACS), to be prevalent in over 20% of patients 
in the early post-operative phase. RHF is furthermore, 
associated with an 18% excess in mortality at one year 
after LVAD implantation [1].  
Several important predictors of RHF were identified 
during this study, including high right atrial to 
pulmonary capillary wedge pressure, low hemoglobin, 
need of multiple intravenous inotropes, INTERMACS 
Class 1-3, and severe RV dysfunction on echo-
cardiography. These readily available pre-operative 
predictors were used to develop the EUROMACS-RHF 
risk score, a simple 5-item scoring system for the pre-
diction of early RHF after LVAD implantation (Figure 
1).  
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The RV is a non-spherical shaped thin muscle structure 
of which the function depends on multiple factors. In 
brief the RV performance depends on systemic venous 
return (pre-load), contractility of the RV free wall and 
interventricular septum, RV afterload, and pericardial 
compliance. Due to the inherent myofiber structure, the 
tri-chamber geometry of the RV, and the interdependent 
relationship of the RV and pulmonary circulation, the 
RV stroke volume is highly sensitive to changes in 
pressure (afterload) rather than volume. Thus, in 
contrast to a tolerant left ventricle, increase RV after-
load could lead to significant drop in RV performance 
and thus reduced cardiac output.   
The unique and complex interaction between the venous 
systemic and pulmonary circuits, the two components of 
the right heart circulatory system, makes the RHF 
syndrome a complex disease, which currently lacks a 
universal definition. This is reflected in the wide 
distribution of the incidence of RHF following LVAD 
implantation (4%-50%).(1) A reasonable definition of 
severe RHF after LVAD, was used by our group for the 
EUROMACS-RHF risk score [1]. , as a combination of 
elevated central venous pressure and need for RV 
support; either mechanical via a RV assist device or 
pharmacological via the use of continuous intravenous 
inotropic support or pulmonary vasodilators such as 
inhaled NO.  
The art of medicine is tackling RHF before it reaches 
the point of no return. The 5 common pillars of RHF 
therapy includes optimization of preload, contractility 
enhancement, afterload reduction, prevention of organ 
damage, and treatment of the underlying cause.  
Improvement of the afterload can be achieved though 
reduction of pulmonary resistance via NO vasodilators. 
In addition, inotropic support or mechanical circulatory 
support can be utilized to enhance contractility. Late 
intervention is associated with secondary organ damage 
including venous and gastrointestinal congestions, acute 
kidney injury and liver dysfunction, perpetuating a 
vicious circle of further aggravating fluid retention and 
worsening RHF, eventually resulting in inevitable 
multi-organ failure. These grave outcomes are evident 
from the two-fold increased mortality after LVAD 
implantation in patients with RHF at six months. 
Emphasizing the need of pre-operative optimization of 
the RV function. However, previous risk scores for the 
prediction of RHF lacked discriminative power or 
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Figure 1. The 5 pillars of Right Heart Failure  syndrome.
Intact  pericardium  or  pericardial  disease  interact  as  an  extra
hemodynamic player of the ventricular interdependence. Abbre‐
viation: GIT: gastrointestinal tract.  
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external validation. The EUROMACS-RHF risk score, 
which outperformed previously published risk scores, 
could be utilized for the identification of candidates for 
RV support. Furthermore, the pre-operative risk 
determined with the EUROMACS-RHF risk score 
could assist in the decision process, preoperative pre-
paration, and in determining the optimal timing of 
surgery. Finally, it is important to inform patients about 
their risk of RHF, especially in older patients receiving 
DT, considering there is no opportunity for bailout 
therapy for these patients.   
The RV has been stated as the forgotten ventricle. 
Luckily, this young field in medicine enjoys arising 
interest and recognition of the devastating consequences 
of RHF. Building evidence and thus improving 
therapeutic strategies requires more research. Starting of 
with the identification of the natural history of RV 
changes after LVAD implantation. Furthermore, due to 
the fact that all therapeutic options for RHF remain 
empiric, clinical trials are warranted. Therefore, we 
recently set up a multicenter longitudinal study, the 
EuroEchoVAD Study (NCT03552679), aiming at 
clinical, hemodynamic, and echocardiographic quan-
tification and prediction of the time course of RV 
function to ultimately redefine RHF in order to identify 
optimal management strategies after LVAD implanta-
tion. The enrollment in the EuroEchoVAD study is 
ongoing with an expected 600 patients at over 30 
international sites.  
In conclusion, the largest European registry of 
mechanical circulatory support revealed that RHF is 
very prevalent and manifest in the early period after 
LVAD implantation and that RHF was associated with 
an increased mortality. The EUROMACS-RHF risk 
score identifies high-risk patients for RHF in whom 
timely RV support should be considered. Clinical trials 
are warranted to determine optimal treatment strategies 
for patients at high-risk for RHF. 
  
REFERENCES 
 
1.   Soliman  OI,  et  al.  Circulation.  2018;  137:891–906. 
https://doi.org/10.1161/CIRCULATIONAHA.117.030543 
 
Osama  Soliman:  Department  of  Cardiology  the 
Thoraxcenter,  Erasmus  Medical  center  Rotterdam, 
Rotterdam, The Netherlands 
Correspondence: Osama Soliman 
Email:  o.soliman@erasmusmc.nl 
Keywords:  heart  failure,  right‐sided  heart  failure, 
ventricular assist device, outcome 
Copyright:  Soliman  et  al.  This  is  an  open‐access  article 
distributed  under  the  terms  of  the  Creative  Commons 
Attribution License (CC BY 3.0), which permits unrestricted 
use,  distribution,  and  reproduction  in  any  medium, 
provided the original author and source are credited 
 
Received:  October 13, 2018 
Published: December 13, 2018 
  
www.aging‐us.com                      8                                                                                 AGING
